Michael Boyne, Ph.D.

Michael Boyne, PhD is an accomplished scientific professional and an unabashed drug developer, having served as a regulator, consultant, and executive in biotech for over 15 years. Currently, Michael is a Co-Founder and Principal of CatalystBio, a Global Life Sciences Advisory Firm dedicated to moving first-in-class, first-in kind technologies off the bench and into the clinic. Michael also serves as the CEO and Co-Founder of BioSynthera, INC which is developing the next generation of therapeutics for clotting/bleeding disorders. Prior to founding CatalystBio and BioSynthera, he was most recently the VP of Product Development and Analytics at COUR, where he led the growth of a five-person virtual company to a 50-person operating company and built out manufacturing, quality, research and development, program management, and regulatory functions. He also led both internal and external diligence teams. Before joining COUR, he was a Senior Consultant at BioTechLogic, advising pharmaceutical manufacturers on drug development and CMC strategy, including drafting, reviewing, and authoring CTDs for regulatory submissions. Prior to consulting, he was a Research Chemist in the Division of Pharmaceutical Analysis at the US Food and Drug Administration, where he established a laboratory developing on applying modern analytical technologies to evaluate and regulate complex therapeutics (generics, biologics, and NCE’s). Michael has authored nearly 50 peer-reviewed publications and is an internationally recognized speaker on applying modern analytical technologies to drug development. He was the chair of the 15th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry and a founding member of the CASSS meeting on Cell and Gene Therapies. He currently serves on the Executive Advisory Board for Northwestern’s Chemistry of Life Process Institute and is the Treasurer of the Gower Foundation. Michael was a postdoctoral scholar at Washington University Medical School in Saint Louis, where he was an American Cancer Society/Canary Foundation Fellow in Early Detection. Michael has a BA in Chemistry from Northwestern University, Evanston, IL, and a PhD in Chemistry from the University of Illinois Urbana-Champaign.